Literature DB >> 14508524

Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.

Thomas Harnois1, Bruno Constantin, Agnès Rioux, Eddy Grenioux, Alain Kitzis, Nicolas Bourmeyster.   

Abstract

The p210(bcr-abl) and p190(bcr-abl) fusion proteins, respectively responsible for chronic myelogenous leukemia and acute lymphoblastic leukemia, present deregulated tyrosine kinase activity and abnormal localization. The Dbl homology domain of Bcr, activating Rho GTPases, is present in p210(bcr-abl), but absent in p190(bcr-abl). We investigated the interaction of Bcr-Abl chimeras and Rho proteins by coimmunoprecipitation, pull-down experiments and GEF activity measurement. RhoA, Rac1 and Cdc42 interact in vivo with p210(bcr-abl) only. Moreover, the three types of GTPases are activated in vitro and in vivo by p210(bcr-abl). Nevertheless, Rac1 and Cdc42, but not RhoA, are activated by p190(bcr-abl) in vitro and in vivo. Part of this GEF activity of p190(bcr-abl) is probably attributable to p95(vav), which is complexed with both p190(bcr-abl) and p210(bcr-abl) in an activated form. p160(bcr), also in complex with Bcr-Abl, presents no GEF activity in p190(bcr-abl)-expressing cells. These results suggest that differential activation of Rho proteins should play a major role in Bcr-Abl-induced leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508524     DOI: 10.1038/sj.onc.1206626

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity.

Authors:  Galit Lazer; Liron Pe'er; Marganit Farago; Kazuya Machida; Bruce J Mayer; Shulamit Katzav
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Afsar A Mian; Anna Metodieva; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.

Authors:  Young Jin Cho; Bin Zhang; Vesa Kaartinen; Leena Haataja; Ivan de Curtis; John Groffen; Nora Heisterkamp
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 4.  The diverse roles of Rac signaling in tumorigenesis.

Authors:  Natalie A Mack; Helen J Whalley; Sonia Castillo-Lluva; Angeliki Malliri
Journal:  Cell Cycle       Date:  2011-05-15       Impact factor: 4.534

5.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

6.  Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Wei-Hong Zhao; Yan Tan
Journal:  Med Oncol       Date:  2014-01-11       Impact factor: 3.064

7.  Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.

Authors:  Amitava Sengupta; Ashley M Ficker; Susan K Dunn; Malav Madhu; Jose A Cancelas
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

8.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Authors:  Margaret Nieborowska-Skorska; Piotr K Kopinski; Regina Ray; Grazyna Hoser; Danielle Ngaba; Sylwia Flis; Kimberly Cramer; Mamatha M Reddy; Mateusz Koptyra; Tyrone Penserga; Eliza Glodkowska-Mrowka; Elisabeth Bolton; Tessa L Holyoake; Connie J Eaves; Sabine Cerny-Reiterer; Peter Valent; Andreas Hochhaus; Timothy P Hughes; Heiko van der Kuip; Martin Sattler; Wieslaw Wiktor-Jedrzejczak; Christine Richardson; Adrienne Dorrance; Tomasz Stoklosa; David A Williams; Tomasz Skorski
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

Review 9.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Authors:  E K Thomas; J A Cancelas; Y Zheng; D A Williams
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

10.  The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Authors:  S Sahay; N L Pannucci; G M Mahon; P L Rodriguez; N J Megjugorac; E V Kostenko; H L Ozer; I P Whitehead
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.